Y.D. More Investments Ltd Increases Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Y.D. More Investments Ltd increased its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 73.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,615,900 shares of the company’s stock after acquiring an additional 683,150 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 1.8% of Y.D. More Investments Ltd’s portfolio, making the stock its 12th biggest position. Y.D. More Investments Ltd owned 0.14% of Teva Pharmaceutical Industries worth $32,641,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TEVA. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $41,000. Cromwell Holdings LLC increased its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares in the last quarter. MAI Capital Management raised its stake in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Rothschild Investment LLC raised its stake in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after purchasing an additional 1,348 shares during the last quarter. Finally, LRI Investments LLC increased its holdings in Teva Pharmaceutical Industries by 246.0% in the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after buying an additional 2,000 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA traded down $1.13 during trading hours on Friday, hitting $33.20. 1,517,044 shares of the stock traded hands, compared to its average volume of 10,269,570. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The company has a market cap of $38.17 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 11.42 and a beta of 0.70. The stock has a 50 day moving average price of $32.49 and a 200 day moving average price of $24.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same period last year, the firm earned $0.71 EPS. The company’s revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday. The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Finally, Piper Sandler raised their target price on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.